INMedD_logo
Yellow Bar

Innovative New Medicine

Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, expensive, difficult, and inefficient process with a low rate of new therapeutic discovery.

Steady and significant increases in R&D spending have not increased the number of new drug applications. This relentless increase in new drug development costs has led to concerns about stagnation in the drug industry. Evidence of this concern is clear in the recent launch of the FDA Critical Path Initiative to revitalize the discovery and development process, and begin to improve the introduction of new medicines to meet an increasing burden of unmet medical needs.

Yellow Bar